FDA Clears Invokana for CV Prevention in T2D

Join our community to access additional content!

CRT Community

$0.00

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Join Now!
Already have an account? Login Now

CRT Community Premium

$450 Annually

Register for Meetings

“In The News” & “Cardiovascular Marketplace” Content Access

Listen to Podcasts

Watch On-Demand Content

CardioTube Access

Access to Recorded Live Broadcasts from CRTvirtual Meetings, DMV, & Cath Conference

Access Recorded Interviews

Download PPT Slide Decks

Complimentary subscription to electronic version of the CRM Journal

Access to CRT Meeting Registration Discounts

CRT Premium Content, including on-demand videos and presentation downloads

Join Now!
Already have an account? Login Now
News

FDA Clears Invokana for CV Prevention in T2D

Posted: 10/31/2018
Author:
Nicole Lou, Contributing Writer, MedPage Today
October 31, 2018
2018 News Articles

First oral diabetes drug to win this indication

The SGLT2 inhibitor canagliflozin (Invokana) was given the green light by the FDA for the prevention of myocardial infarction, stroke, and death among patients with type 2 diabetes who have established cardiovascular disease, Janssen announced.

Most Viewed Pages

TARGET BP I: Alcohol-Mediated RDN Shows ‘Modest but Significant’ 24-Hour Ambulatory Systolic BP Drop vs. Sham Procedure at 3 Months

Coronary Sinus Reducer Relieves Angina, but Mechanism Remains Unclear: ORBITA-COSMIC Trial

TAVR Noninferior to SAVR for All-Cause Mortality, Stroke at 1 Year in Low- to Intermediate-Risk Patients: DEDICATE

The DanGer Shock Trial & Panel Discussion

Web App Proves Effective in Aiding Patients’ Self-Selection for OTC Rosuvastatin: TACTiC Trial

Explore the Site

Stay Connected

CRT Group Foundation is a not for profit corporation dedicated to providing educational services in the field of cardiology through the website, CRTonline.org and the Cardiovascular Research Technologies (CRT) annual symposium. CRT focuses on the advances and changes in the field of cardiovascular medicine. CRT is designed to provide access to the world’s leading clinicians and the latest research in order to improve practice and treatment outcomes for a variety of health care professionals.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details

Join our community to access additional content!

CRT Community

CRT Community Premium

News

FDA Clears Invokana for CV Prevention in T2D

First oral diabetes drug to win this indication

Most Viewed Pages

Explore the Site

Stay Connected